Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer

doi:10.16352/j.issn.1001-6325.2023.12.1861

Abstract

Abstract: Objective To explore the effect of paclitaxel with carboplatin combined chemotherapy on hemocyte related indexes,vascular endothelial growth factor (VEGF) and tumor markers in ovarian cancer (OC) patients. Methods OC patients combined chemotherapy (CC) group and ovarian benign tumor control group with 50 cases in each. The pathological changes in the ovarian cells were observed by HE staining and the expression of VEGF was observed by immunohistochemical staining (IHC).Blood cell was counted by flow cytometry (FC). Serum carbohydrate antigen 125 (CA125) and human epididymal protein 4 (HE4) were measured by electrochemical luminescence (ECL). Results Compared with control group, the ovarian tissue structure was disordered and the cell atypia was obvious in OC.VEGF expression was significantly enhanced. Platelet count (PLT), CA125 and HE4 were significantly increased (P＜0.01). However,necrotic cells were observed in ovarian tissue of CC group.VEGF expression was inhibited.PLT count and the level of CA125 and HE4 were significantly lower than those of control group after chemotherapy(P＜0.01). Conclusions Combined chemotherapy may regulate the level of VEGF, CA125 and HE4 in OC patients.

Key words: ovarian cancer, combined chemotherapy, blood cells, VEGF, tumor marker

CLC Number:

R730.231

TAN Shufen, YANG Xielan, YANG Linlin, LI Shuqing. Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer[J]. Basic & Clinical Medicine, 2023, 43(12): 1861-1865.

References 16

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics[J].CA Cancer J Clin,2018, 68:7-30.
[2]	Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia,Canada, Denmark, Norway, Sweden, and the UK,1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data[J]. Lancet, 2011,377:127-138.
[3]	Teliga-Czajkowska J, Sienko J, Jalinik K,et al. Plasminogen activator inhibitor type1 in blood at onset of chemotherapy unfavorably affects survival in primary ovarian cancer[J]. Adv Exp Med Biol,2019,5: 47-54.
[4]	Yang J, Jin Y, Cheng S,et al.Clinical signifcance for combined coagulation indexes in epithelial ovarian cancer prognosis[J]. J Ovarian Res,2021,14:106-116.
[5]	Cho MS,Li J,Gonzalez-Delgado R,et al. The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer[J]. Blood Adv, 2021, 5:1947-1951.
[6]	Falanga A, Marchetti M, Russo L.The mechanisms of cancer-associated thrombosis[J]. Thromb Res, 2015,135:S8-S11.
[7]	Jaiswal RK, Varshney AK, Yadava PK. Diversity and functional evolution of the plasminogen activator system[J]. Biomed Pharmacother,2018,98:886-898.
[8]	Haemmerle M,Taylor ML,Gutschner T,et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling[J]. Nat Commun,2017,8:310.doi:10.1038/s41467-017-00411-z.
[9]	Li W, Tang Y, Song Y, et al. Prognostic role of pretreatment plasma D-Dimer in patients with solid tumors: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018, 45: 1663-1676.
[10]	Lal I, Dittus K,Holmes CE.Platelets, coagulation and fibrinolysis in breast cancer progression[J].Breast Cancer Res,2013, 15:207-219.
[11]	吴梦,娄鉴芳,黄珮珺,等. 卵巢癌细胞通过p38 MAPK通路促进CD8+调节T细胞的生成[J]. 基础医学与临床, 2016, 36: 167-172.
[12]	Bortot B, Mangogna A, Peacock B,et al.Platelet activation in ovarian cancer ascites: assessment of GPIIb/IIIa and PF4 in small extracellular vesicles by nano-flow cytometry analysis[J]. Cancers, 2022, 14:4100 doi:10.3390/cancers14174100.
[13]	李少儒,秦海霞,刘珊珊,等.miR-493-5p抑制人卵巢癌细胞系SKOV3增殖和迁移[J].基础医学与临床,2021,41:1749-1755.
[14]	Collinson FJ, Seligmann J, Perren TJ.Ovarian cancer: advances in first-line treatment strategies with a particular focus on antiangiogenic agents[J].Current oncol Rep,2012,14:509-518.
[15]	Rubio-Jurado B, Balderas-Penal M, Garcia-Lunae E, et al. Obesity, thrombotic risk, and inflammation in cancer[J]. Adv Clin Chem, 2018, 85: 71-89.
[16]	Reiser E,Pils D,Grimm C,et al.Defining models to classify between benign and malignant adnexal masses using routine laboratoryparameters[J].Cancers, 2022,14:3210. doi:10.3390/cancers14133210.